ViraPower™ Adenoviral Promoterless Gateway™ Expression Kit
Product Image
Invitrogen™

ViraPower™ Adenoviral Promoterless Gateway™ Expression Kit

The ViraPower™ Adenoviral Promoterless Gateway™ Expression Kit combines Invitrogen’s ViraPower™ Adenoviral and Gateway™ technologies to facilitate easy recombination-based cloning and了解更多信息
Have Questions?
货号数量
K494000
又称 K4940-00
1 kit
货号 K494000
又称 K4940-00
价格(CNY)
24,039.00
Each
添加至购物车
数量:
1 kit
价格(CNY)
24,039.00
Each
添加至购物车
The ViraPower™ Adenoviral Promoterless Gateway™ Expression Kit combines Invitrogen’s ViraPower™ Adenoviral and Gateway™ technologies to facilitate easy recombination-based cloning and adenoviral-based, transient expression of a target gene in dividing and non-dividing mammalian cells. The pAd⁄PL-DEST™ vector allows generation of an adenovirus containing the target gene where expression is driven by a promoter of choice. Alternatively, the vector may also be used to express small RNA molecules from their appropriate promoters.

Advantages
• High efficiency and rapid recombination cloning
• Produces high titer adenoviral stocks
• Efficient delivery of the gene to dividing and non-dividing mammalian cells in vitro or in vivo
• Allows gene of interest to be controlled by a promoter of choice
• Produces replication-incompetent virus for enhanced biosafety of the system
• Amenable for use in high-throughput applications

Key Features
• Gateway™ Technology for efficient and rapid cloning
• Promoterless vector that allows gene of interest to be controlled by a promoter of choice
• Human Ad5 sequences (ΔE3) and Viral Inverted Terminal Repeats (ITRs) for packaging of the expression construct into virions
• Ampicillin selection marker

Kit includes
• pAd⁄PL-DEST™ Gateway™ Vector (6 μg. Cat. No. V493-20)
• 293A Cell Line (3 x 106 cells, frozen. Cat. No. R705-07)

For research use only. Not intended for any therapeutic or diagnostic use.
仅供科研使用。不可用于诊断程序。
规格
构成或诱导系统组成型
输送类型腺病毒
适用于(应用)克隆您自己的启动子,病毒表达
产品类型Adenoviral Expression Kit
数量1 kit
载体pAd
克隆方法Gateway
产品线Gateway, ViraPower
促进剂None (Promoterless)
蛋白标记Untagged
Unit SizeEach
内容与储存
• pAd/PL-DEST Gateway™ Vector (Store at -20°C)
• 293A Cell Line (Store in liquid nitrogen)

常见问题解答 (FAQ)

可以使用BP Clonase酶和LR Clonase酶替代BP Clonase II 酶LR Clonase II酶进行BP/LR Clonase反应的一步法实验方案吗?

在BP/LR Clonase反应的一步法实验方案中,不建议用BP Clonase酶和LR Clonase酶替代BP Clonase II 酶/LR Clonase II酶,因为这样的重组效率非常低。

有推荐的一步式BP/LR重组实验方案吗?

有的,我们能提供针对BP/LR Clonase反应的一步式实验方案DNA可以在一步反应后被克隆到目的载体中,从而节省了您的时间和金钱。

如果丢失了入门克隆,如何将目的基因从一个Gateway兼容的表达克隆转移到一个新的目的载体?

建议使用一个供体载体进行一次BP反应以获得一个入门克隆。然后将这一入门克隆和目的载体进行一次LR反应以获得新的表达克隆。

我可以单独购买5X LR Clonase缓冲液或5X BP Clonase缓冲液吗?

5X LR Clonase缓冲液或5X BP Clonase缓冲液不作为单独产品出售。它们作为酶试剂盒的一部分进行销售。

是否提供用于在植物内表达的Gateway载体吗?

我们不提供任何用于在植物内表达的Gateway载体。

引用和文献 (1)

引用和文献
Abstract
Depletion of Chk1 leads to premature activation of Cdc2-cyclin B and mitotic catastrophe.
Authors:Niida H, Tsuge S, Katsuno Y, Konishi A, Takeda N, Nakanishi M,
Journal:J Biol Chem
PubMed ID:16159883
Mitotic catastrophe occurs as a result of the uncoupling of the onset of mitosis from the completion of DNA replication, but precisely how the ensuing lethality is regulated or what signals are involved is largely unknown. We demonstrate here the essential role of the ATM/ATR-p53 pathway in mitotic catastrophe from ... More